Advertisement

Topics

Marketing application for thrombocytopenia drug accepted by EMA

05:56 EDT 12 Oct 2018 | SmartBrief

Rigel Pharmaceuticals' marketing application for Tavalisse, or fostamatinib disodium hexahydrate, indicated for the treatment -More

Original Article: Marketing application for thrombocytopenia drug accepted by EMA

NEXT ARTICLE

More From BioPortfolio on "Marketing application for thrombocytopenia drug accepted by EMA"

Advertisement
Quick Search
Advertisement
Advertisement